Everything below concerns DAC group. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-28. Numbers and descriptions here follow the published literature rather than marketing material.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Activated carbon, in 50% w/w combination with celite, is used as stationary phase in low-pressure chromatographic separation of carbohydrates (mono-, di-, tri-saccharides) using ethanol solutions (5–50%) as mobile phase in analytical or preparative protocols. Activated carbon is useful for extracting the direct oral anticoagulants (DOACs) such as dabigatran, apixaban, rivaroxaban and edoxaban from blood plasma samples. For this purpose it has been made into "minitablets", each containing 5 mg activated carbon for treating 1ml samples of DOAC. Since this activated carbon has no effect on blood clotting factors, heparin or most other anticoagulants this allows a plasma sample to be analyzed for abnormalities otherwise affected by the DOACs. Carbon adsorption has numerous applications in removing pollutants from air or water streams both in the field and in industrial processes such as:
RNA polymerase III performs "intrinsic-like" termination. The majority of genes transcribed by RNAP III have a poly(dT) region. However, although poly(dT) pauses every RNA polymerase, it alone cannot be insufficient; some other mechanism must destabilize the clamp. In RNAP III, some poly(dT) sites are indeed occasionally read-through: some genes have multiple such regions, allowing transcripts of different lengths to be produced. The instability of rU:dA hybrids likely is essential to termination by RNAP III. Parts of core subunits C1 and C2, as well as "subcomplexes" C53/37 and C11 are functionally important. A number of extraneous factors can modify the termination behavior. Rho factor WebGeSTer Trp operon
In 2024, Apple Inc. released Apple Vision Pro. This device features hardware such as dual panels that offer 24 million pixels, surpassing devices such as the Oculus Rift. The integration of the R1 chip, working in tandem with the M2 chip, results in a polling rate of 12 milliseconds, getting rid of the dizzying latency issues that were prevalent in previous devices.
Dapagliflozin Canagliflozin Empagliflozin Remogliflozin The side effects of SGLT2 inhibitors are derived directly from their mechanism of action; these include an increased risk of: ketoacidosis, urinary tract infections, candidal vulvovaginitis, and hypoglycemia.
=== Insects === Order Blattodea Blattella germanica, German cockroach (2018) Periplaneta americana, American cockroach (2018) Zootermopsis nevadensis, a dampwood termite (2014 Cryptotermes secundus, a drywood termite(2018) Macrotermes natalensis, a higher termite (2014 Order Coleoptera Dendroctonus ponderosae Hopkins, beetle (mountain pine beetle) (2013) Aquatica lateralis, Japanese aquatic firefly "Heike-botaru" (firefly) (2018) Photinus pyralis, Big Dipper firefly (2018) Protaetia brevitarsis, White-spotted flower chafer (2019) Tribolium castaneum Strain:GA-2, beetle (red flour beetle) (2008) Allomyrina dichotoma, Japanese rhinoceros beetle (2022) Pachyrhynchus sulphureomaculatus, Easter Egg Weevil (2021) Order Collembola Family Isotomidae Desoria tigrina, (2021) Family Sminthurididae Sminthurides aquaticus, (2021) Order Diptera Family Calliphoridae Aldrichina grahami, Forensic blowfly (2020) Family Chironomidae Dasypogon diadema, Hunting Robber fly (2019) Parochlus steinend, Antarctic winged midge (2017) Proctacanthus coquilletti, Assassin fly (2017) Family Culicidae (mosquitoes) Aedes aegypti Strain:LVPib12, mosquito (vector of dengue fever, etc.) (2007) Aedes albopictus (2015) Anopheles darlingi Anopheles gambiae Strain: PEST, mosquito (vector of malaria) (2002) Anopheles gambiae Strain: M, mosquito (vector of malaria) (2010) Anopheles gambiae Strain: S, mosquito (vector of malaria) (2010) Anopheles sinensis, mosquito (vector of vivax malaria, lymphatic filariasis and Setaria infections), (2014) Anopheles stephensii Anopheles arabiensis (2015) Anopheles quadriannulatus (2015) Anopheles merus (2015) Anopheles melas (2015) Anopheles christyi (2015) Anopheles epiroticus (2015) Anopheles maculatus (2015) Anopheles culicifacies (2015) Anopheles minimus (2015) Anopheles funestus (2015, 2019) Anopheles dirus (2015) Anopheles farauti (2015) Anopheles atroparvus (2015) Anopheles sinensis (2015) Anopheles albimanus (2015) Culex quinquefasciatus, mosquito (vector of West Nile virus, filariasis etc.) (2010) Family Drosophilidae (fruit flies) Drosophila albomicans, fruit fly (2012) Drosophila ananassae, fruit fly (2007) Drosophila biarmipes, fruit fly (2011) Drosophila bipectinata, fruit fly (2011) Drosophila erecta, fruit fly (2007) Drosophila elegans, fruit fly (2011) Drosophila eugracilis, fruit fly (2011) Drosophila ficusphila, fruit fly (2011) Drosophila grimshawi, fruit fly (2007) Drosophila kikkawai, fruit fly (2011) Drosophila melanogaster, fruit fly (model organism) (2000) Drosophila mojavensis, fruit fly (2007) Drosophila neotestacea, fruit fly (transcriptome 2014) Drosophila persimilis, fruit fly (2007) Drosophila pseudoobscura, fruit fly (2005) Drosophila rhopaloa, fruit fly (2011) Drosophila santomea, fruit fly () Drosophila sechellia, fruit fly (2007) Drosophila simulans, fruit fly (2007) Drosophila takahashi, fruit fly (2011) Drosophila virilis, fruit fly (2007) Drosophila willistoni, fruit fly (2007) Drosophila yakuba, fruit fly (2007) Family Phoridae Megaselia abdita, scuttle fly (transcriptome 2013) Family Psychodidae (drain flies) Clogmia albipunctata, moth midge (transcriptome 2013) Family Sarcophagidae (flesh flies) Sarcophaga Bullata, Flesh fly (2019) Family Syrphidae (hoverflies) Episyrphus balteatus, hoverfly (transcriptome 2011) Order Hemiptera Acyrthosiphon pisum, aphid (pea aphid) (2010) Ericerus pela, Chinese wax scale insect (2019) Laodelphax striatellus, small brown planthopper (2017) Lycorma delicatula, spotted lanternfly (2019) Rhodnius prolixus, kissing-bug (2015) Rhopalosiphum maidis, Corn leaf aphid (2019) Sitobion miscanthi, Indian grain aphid (2019) Triatoma rubrofasciata, assassin bug (2019) Order Hymenoptera Acromyrmex echinatior colony Ae372, ant (Panamanian leafcutter) (2011) Apis mellifera, bee (honey bee), (model for eusocial behavior) (2006) Atta cephalotes, ant (leaf-cutter ant) (2011) Camponotus floridanus, ant (2010) Cerapachys biroi, ant (clonal raider ant)(2014) Euglossa dilemma, Green orchid bee (2017) Harpegnathos saltator, ant (2010) Lasius niger, ant (black garden ant)(2017) Linepithema humile, ant (Argentine ant) (2011) Nasonia giraulti, wasp (parasitoid wasp) (2010) Nasonia longicornis, wasp (parasitoid wasp) (2010) Nasonia vitripennis, wasp (parasitoid wasp; model organism) (2010) Netelia fuscicornis, wasp (parasitoid wasp) (2024) Nomia Melanderi, Alkali bee (2019) Pogonomyrmex barbatus, ant (red harvester ant) (2011) Solenopsis invicta, ant (fire ant) (2011) Order Lepidoptera Abrostola tripartita Hufnagel, Spectacle (2021) Achalarus lyciades, Hoary Edge Skipper (2017) Ahamus jianchuanensis, Jianchuan ghost moth (2024) Antharaea yamamai, Japanese oak silk moth (2019) Arctia plantaginis, Wood tiger moth (2020) Bicyclus anynana, squinting bush brown (2017) Bombyx mori Strain:p50T, moth (domestic silk worm) (2004) Calycopis cecrops, Red-Banded Groundstreak (2016) Calycopis isobeon, Dusky-Blue Groundstreak (2016) Coenonympha arcania, Pearly Heath (2024) Cydia pomonella, codling moth (2019) Danaus plexippus, monarch butterfly) (2011) Erebia cassioides, Common Brassy Ringlet (2025) Heliconius melpomene, butterfly (2012) Keiferia lycopersicella, Tomato pinworm (2024) Melitaea cinxia, Glanville fritillary butterfly (2014) Megathymus ursus violae, bear giant skipper butterfly (2018) Morpho helenor, Common blue morpho (2023) Morpho achilles, Blue-banded morpho (2023) Morpho deidamia (2023) Papilio bianor, Chinese peacock butterfly (2019) Phthorimaea absoluta, Tomato leafminer (2024) Pieris rapae, small cabbage white butterfly (2016) Plodia interpunctella, Indianmeal moth (2022) Plutella xylostella, moth (diamondback moth) (2013) Scrobipalpa atriplicella, Goosefoot groundling moth (2024) Spodoptera frugiperda, Fall armyworm (2017) Thitarodes armoricanus, Himalaya ghost moth (2024) Thitarodes xiaojinensis, Xiaojin ghost moth (2024) Troides aeacus, Golden birdwing (2024) Eudocima phalonia, fruit-piercing moth (2017) Order Orthoptera Locusta migratoria, migratory locust (2014) Schistocerca gregaria, desert locust (2020) Gryllus bimaculatus, two-spotted cricket (2021) Order Phthiraptera Pediculus humanus, louse (sucking louse; parasite) (2010) Menopon gallinae, Poutlry shaft louse (2024) Psocoptera Liposcelis brunnea, booklouse (2022) Order Raphidioptera Venustoraphidia nigricollis, black-necked snakefly (2023) Order Trichoptera Eubasilissa regina, purple caddisfly (2022,) Stenopsyche tienmushanensisi, Caddisfly (2018) Order Mantodea Tenodera sinensis, chinese praying mantis (2023)
Sources: en.wikipedia.org
The American Journal of Clinical Pathology is a monthly peer-reviewed medical journal covering clinical pathology. It was established in 1931 and is published by Oxford University Press. It is the official journal of the American Society for Clinical Pathology and the Academy of Clinical Laboratory Physicians and Scientists. The editor-in-chief is Steven H. Kroft (Medical College of Wisconsin). According to the Journal Citation Reports, the journal has a 2020 impact factor of 2.493.
== History == B&O Supprettes (the name is derived from the generic term 'belladonna/opium suppository') is an "unapproved" drug according to the Food and Drug Administration (FDA) – that is, the drug existed before the Food, Drug and Cosmetic Act of 1938. Accordingly, the compound has never undergone specific medical trials, and its efficacy has never been required to be demonstrated. The FDA has put pressure on the manufacturers of this drug for this reason. The original manufacturer of the Supprettes, Eli Lilly and Company, has long since lost any patent to the drug. Amerifit, which manufactured generic Supprettes prior to 2008, was cautioned by the FDA due to the unapproved nature of the drug combination. Since 2008, Paddock Laboratories has manufactured a generic version of the Supprettes after working with the FDA on marketing issues related to the unapproved nature of the drug.
=== Example: Azathioprine Therapy === Azathioprine is an immunomodulator for inflammatory bowel disease, for instance. Its metabolite relies on two different enzymes (TPMT and NUDT15) to eliminate its effect on our body during its metabolism. If the patient has the phenotype of the enzymes that metabolize it poorly, i.e., the poor metabolizer, more toxic metabolites are accumulated in the body. Thus, the patient has a greater risk of the related side-effect. The side effect causes the adjustment of dosage or switching to another drug.
Income inequality has traditionally been low in Denmark. According to OECD figures, in 2000 Denmark had the lowest Gini coefficient of all countries. However, inequality has increased during the last decades. According to data from Statistics Denmark, the Gini coefficient for disposable income has increased from 22.1 in 1987 to 29.3 in 2017. The Danish Economic Council found in an analysis from 2016 that the increasing inequality in Denmark is due to several components: Pre-tax labour income is more unequally distributed today than before, capital income, which is generally less equally distributed than labour income, has increased as share of total income, and economic policy is less redistributive today, both because public income transfers play a smaller role today and because the tax system has become less progressive. In international comparisons, Denmark has a relatively equal income distribution. According to the CIA World Factbook, Denmark had the twentieth-lowest Gini coefficient (29.0) of 158 countries in 2016. According to data from Eurostat, Denmark was the EU country with the seventh-lowest Gini coefficient in 2017. Slovakia, Slovenia, Czechia, Finland, Belgium and the Netherlands had a lower Gini coefficient for disposable income than Denmark.
A true ANP stationary phase will be able to function in both the reversed phase and normal phase modes with only the amount of water in the eluent varying. Thus a continuum of solvents can be used from 100% aqueous to pure organic. ANP retention has been demonstrated for a variety of polar compounds on the hydride based stationary phases. Recent investigations have demonstrated that silica hydride materials have a very thin water layer (about 0.5 monolayer) in comparison to HILIC phases that can have from 6–8 monolayers.[1] In addition the substantial negative charge on the surface of hydride phases is the result of hydroxide ion adsorption from the solvent rather than silanols.[2]
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.